Fig. 6: Effect of clomiphene, targocil, and murJ overexpression on the expression of vraX-lux.

a, b Effect of clomiphene treatment on the vraX-lux induction by moenomycin (Moe-0.08, at a final concentration of 0.08 µg/ml) (a) and tunicamycin (Tuni-0.5; 0.5 µg/ml) (b). Clo-50, Clomiphene at a final concentration of 50 µg/ml. Data from n = 4 biological replicates are reported as the mean ± SD. c, d Effect of targocil treatment on the vraX-lux induction by moenomycin (Moe-0.08, at a final concentration of 0.08 µg/ml) (c) and tunicamycin (Tuni-0.5; 0.5 µg/ml) (d). Tar-12, targocil at a final concentration of 12 µg/ml. Data from n = 4 biological replicates are reported as the mean ± SD. e, f Effect of murJ overexpression on the expression of vraX-lux in USA300 LAC (e) and RN4220 (f). The expression of vraX-lux in USA300 LAC derivatives grown in TSB medium supplemented with or without moenomycin (at a final concentration of 3 ng/ml) in the absence or presence of anhydrotetracycline (aTc) that induces the tetracycline-inducible xyl/tetO promoter in pYJ335 plasmid. Data from n = 4 biological replicates are reported as the mean ± SD. Statistical analysis was performed using Student’s two-tailed unpaired t-test (USA300/p-murJ versus USA300/pYJ335 at 2 h time point or RN4220/p-murJ versus RN4220/pYJ335 at 3 h time point, as indicated by the arrows).